Management of Anemia in Chronic Kidney Disease

Chronic Renal Disease

Volumn , Issue , 2015, Pages 624-633

  Fernandez, Hilda ^a   Singh, Ajay K ^b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anemia; CKD; Epoetin; Hemoglobin; Kidney disease

Indexed keywords

EID: 84942196452     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-411602-3.00051-2     Document Type: Chapter

References (72)

1. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004, 20(9):1501-1510.
2. Hsu CY, McCulloch CE, Curhan GC Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002, 13(2):504-510.
3. Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004, 19(1):121-132.
4. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005, 68(5):2323-2330.
5. Collins AJ, Ma JZ, Ebben J Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000, 20(4):345-349.
6. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001, 12(11):2465-2473.
7. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006, 17(4):1181-1191.
8. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361(21):2019-2032.
9. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355(20):2071-2084.
10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339(9):584-590.
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355(20):2085-2098.
12. Singh AK Is there a deleterious effect of erythropoietin in end-stage renal disease?. Kidney Int 2011, 80(6):569-571.
13. Singh AK What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?. Curr Opin Nephrol Hypertens 2010, 19(5):420-424.
14. Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013, 28(6):1346-1359.
15. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group.KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2012, (2):279-355.
16. Stancu S, Barsan L, Stanciu A, Mircescu G Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?. Clin J Am Soc Nephrol 2010, 5(3):409-416.
17. Singh AK, Coyne DW, Shapiro W, Rizkala AR Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007, 71(11):1163-1171.
18. Vidt DG Inflammation in renal disease. Am J Cardiol 2006, 97(2A):20A-27A.
19. Levin A, Singer J, Thompson CR, Ross H, Lewis M Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996, 27(3):347-354.
20. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999, 34(1):125-134.
21. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996, 28(1):53-61.
22. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002, 13(4):1084-1090.
23. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002, 40(6):1153-1161.
24. Coyne DW The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012, 82(2):235-241.
25. Fishbane S, Wish JB A physician's perseverance uncovers problems in a key nephrology study. Kidney Int 2012, 82(2):135-137.
26. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012, 60(3):390-401.
27. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 2013, 37(6):549-558.
28. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation 2011, 124(25):2903-2908.
29. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013, 62(5):849-859.
30. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010, 363(12):1146-1155.
31. Horl WH Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013, 73(2):117-130.
32. Gertz B, Kes P, Essaian A, Bias P, Buchner A, Zellner D Epoetin theta: efficacy and safety of subcutaneous administration in anemic pre-dialysis patients in the maintenance phase in comparison to epoetin beta. Curr Med Res Opin 2012, 28(7):1101-1110.
33. Horl WH, Locatelli F, Haag-Weber M, Ode M, Roth K Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10--12g/dl. Clin Nephrol 2012, 78(1):24-32.
34. Haag-Weber M, Eckardt KU, Horl WH, Roger SD, Vetter A, Roth K Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-alpha (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012, 77(1):8-17.
35. Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012, 81(8):727-732.
36. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, et al. Quality of original and biosimilar epoetin products. Pharm Res 2011, 28(2):386-393.
37. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999, 10(11):2392-2395.
38. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003, 18(2):362-369.
39. Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, et al. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012, 27(6):2303-2311.
40. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006, 1(6):1211-1215.
41. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R, Board E-EEA Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009, 24(2):348-354.
42. Koch M, Henrich D, Faust J, Nawka J, Rath T, Wanner C Initial use of once-monthly administration of C.E.R.A. is effective and safe in correcting renal anemia in non-dialysis patients: the MERCUR trial. Clin Nephrol 2012, 78(3):189-197.
43. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998, 339(9):578-583.
44. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008, 3(2):337-347.
45. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002, 346(7):469-475.
46. Rossert J, Casadevall N, Eckardt KU Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004, 15(2):398-406.
47. Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 2011, 126(2):114-118.
48. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004, 363(9423):1768-1771.
49. Macdougall IC Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005, 20(Suppl 4):iv 9-iv15.
50. Andrade J, Taylor PA, Love JM, Levin A Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. Nephrol Dial Transplant 2005, 20(11):2548-2551.
51. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002, 13(9):2381-2383.
52. Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009, 361(19):1848-1855.
53. Lipschitz DA, Cook JD, Finch CA A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974, 290(22):1213-1216.
54. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996, 7(12):2654-2657.
55. Besarab A, Coyne DW Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010, 6(12):699-710.
56. Fernandez Rodriguez A, Guerra Prieto MF, Camino Calderon E, Solera Santos J [Iron-deficiency anemia and adult celiac disease]. An Med Interna 1999, 16(4):208-209.
57. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995, 26(2):292-299.
58. Chung M, Chan JA, Moorthy D, Hadar N, Ratichek SJ, Concannon TW, et al. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease: future research needs: identification of future research needs from comparative effectiveness review no 83. Rockville (MD); 2013.
59. Sunder-Plassmann G, Horl WH Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995, 10(11):2070-2076.
60. Fishbane S, Frei GL, Maesaka J Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995, 26(1):41-46.
61. Sepandj F, Jindal K, West M, Hirsch D Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996, 11(2):319-322.
62. Appelberg R Macrophage nutriprive antimicrobial mechanisms. J Leukoc Biol 2006, 79(6):1117-1128.
63. Byrd TF, Horwitz MA Interferon gamma-activated human monocytes downregulate transferrin receptors and inhibit the intracellular multiplication of Legionella pneumophila by limiting the availability of iron. J Clin Invest 1989, 83(5):1457-1465.
64. Hoen B, Paul-Dauphin A, Hestin D, Kessler M EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998, 9(5):869-876.
65. Hoen B, Paul-Dauphin A, Kessler M Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002, 57(6):457-461.
66. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fe d'Ostiani C, et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 1997, 175(6):1467-1476.
67. Nairz M, Theurl I, Ludwiczek S, Theurl M, Mair SM, Fritsche G, et al. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 2007, 9(9):2126-2140.
68. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004, 38(8):1090-1094.
69. Bridges KR, Hoffman KE The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J Biol Chem 1986, 261(30):14273-14277.
70. Lipschitz DA, Bothwell TH, Seftel HC, Wapnick AA, Charlton RW The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 1971, 20(2):155-163.
71. Deved V, Poyah P, James MT, Tonelli M, Manns BJ, Walsh M, et al. Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54(6):1089-1097.
72. Shahrbanoo K, Taziki O Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. Saudi J Kidney Dis Transpl 2008, 19(6):933-936.